BridgeMD
New treatment option for Endovascular Therapy
Official title Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery
ClinicalTrials.gov ID: NCT07347665
What this study is testing
- What it's testing
- RESCUE-M2O trial is a prospective, open label, blinded endpoint (PROBE), two-arm, randomized, controlled, post-market study to assess the efficacy and safety of endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 84
You may be able to join if
- Acute cerebral infarction
- Aged 18-84 years
- NIHSS score at admission ≥ 8
- Prestroke mRS scores of 0-1 (able to carry out all usual activities)
- Occlusion of the M2 segment of MCA on digital subtraction angiography
You likely can't join if
- Occlusion of the anterior temporal artery, duplicate M1, or accessory M1
- Occlusion of multiple major intracranial arteries
- Difficulty in endovascular access due to tortuous vascular anatomy
- Significant mass effect with midline shift on CT (or MRI)
- Known allergy (more severe than skin rash) to contrast agents
- Evidence of acute intracranial hemorrhage on CT (or MRI)
See the full eligibility criteria
- Acute cerebral infarction
- Aged 18-84 years
- NIHSS score at admission ≥ 8
- Prestroke mRS scores of 0-1 (able to carry out all usual activities)
- Occlusion of the M2 segment of MCA on digital subtraction angiography
- ASPECTS ≥ 8 or DWI-ASPECTS ≥ 8
- Ineligible or failed intravenous tPA (no recanalization within 30 min after injection)
- Randomization can be completed within 24 h from the last known well time
- EVT can be initiated within 30 min from randomization.
- The patient or their legally authorized representative has signed the informed consent form.
- Occlusion of the anterior temporal artery, duplicate M1, or accessory M1
- Occlusion of multiple major intracranial arteries
- Difficulty in endovascular access due to tortuous vascular anatomy
- Significant mass effect with midline shift on CT (or MRI)
- Known allergy (more severe than skin rash) to contrast agents
- Evidence of acute intracranial hemorrhage on CT (or MRI)
- Pregnant or potentially pregnant
- Clinical evidence of chronic occlusion
- High risk of hemorrhage (platelet \ 50 sec or PT-INR \> 3.0)
- Participating in any other therapeutic investigational trial
- Judgment of the investigator to be non-compliant or uncooperative during the study
The study team makes the final eligibility decision.
Where it's taking place
- Nishinomiya, Hyōgo, Japan
- Khlong Luang, Changwat Pathum Thani, Thailand
- Can Tho, Can Tho City, Vietnam
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 84 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nishinomiya, Hyōgo, Japan; Khlong Luang, Changwat Pathum Thani, Thailand; Can Tho, Can Tho City, Vietnam. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.